查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
癌症基因治療的全球市場-機會分析及產業預測:各治療(遺傳基因誘導免疫療法，腫瘤溶解性病毒療法，基因轉移)，各終端用戶(醫院，診斷中心，研究機關)(2020年～2030年)
市場調查報告書
商品編碼
1090775

癌症基因治療的全球市場-機會分析及產業預測:各治療(遺傳基因誘導免疫療法，腫瘤溶解性病毒療法，基因轉移)，各終端用戶(醫院，診斷中心，研究機關)(2020年～2030年)

Cancer Gene Therapy Market By Therapy (Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer), By End User (Hospitals, Diagnostic centers, Research Institutes): Global Opportunity Analysis and Industry Forecast, 2020-2030
出版日期: | 出版商: Allied Market Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

全球癌症基因治療的市場規模，預計從2020年的13億8,942萬美元到2030年達到113億5,935萬美元，在預測期間內預計以23.3％的年複合成長率成長。

癌症的盛行率上升，癌症基因治療相對於傳統癌症治療的優點，政府的支援劇增，癌症治療中基因治療的道德接受，生物技術相關資金增加等，成為癌症基因治療市場成長的主要原因。

本報告提供全球癌症基因治療市場相關調查分析，市場形勢，市場分析，企業簡介等系統性資訊。

目錄

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 主要調查結果
    • 主要的投資口袋
  • 波特的五力分析
  • 主要企業的定位
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 市場上的COVID-19影響分析

第4章 癌症基因治療市場:各治療

  • 概要
  • 遺傳基因誘導免疫療法
  • 腫瘤溶解性病毒療法
  • 基因轉移

第5章 癌症基因治療市場:各終端用戶

  • 概要
  • 醫院
  • 診斷中心
  • 研究

第6章 癌症基因治療市場:各地區

  • 市場規模與預測
  • 主要趨勢和機會
  • 北美市場規模與預測:各治療
  • 北美市場規模與預測:各終端用戶
  • 北美市場規模與預測:各國
    • 美國
    • 加拿大
    • 墨西哥
  • 主要趨勢和機會
  • 歐洲市場規模與預測:各治療
  • 歐洲市場規模與預測:各終端用戶
  • 歐洲市場規模與預測:各國
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他的歐洲
  • 主要趨勢和機會
  • 亞太地區市場規模與預測:各治療
  • 亞太地區市場規模與預測:各終端用戶
  • 亞太地區市場規模與預測:各國
    • 日本
    • 中國
    • 澳洲
    • 印度
    • 韓國
    • 其他的亞太地區
  • 主要趨勢和機會
  • 南美、中東、非洲市場規模與預測:各治療
  • 南美、中東、非洲市場規模與預測:各終端用戶
  • 南美、中東、非洲市場規模與預測:各國
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他的南美、中東、非洲

第7章 企業形勢

  • 簡介
  • 主要的成功策略
  • 主要十大公司的產品製圖
  • 競爭儀表板
  • 競爭熱圖
  • 主要的開發

第8章 企業簡介

  • Bristol Myers Squibb Co.
  • Novartis
  • Amgen Inc.
  • Glaxosmithkline PLC
  • Kayropharma Therapeutics
  • Gilead Sciences
  • Adapta Immue
  • Genulex Corporation
  • SynerGene Therapeutics
  • shanghai sunway biotech
Product Code: A02273

Cancer Gene Therapy Market was valued at $1,389.42million in 2020 and is estimated to reach $11,359.35 million by 2030, registering a CAGR of 23.3% from 2021 to 2030. Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. Cancer often has the ability to spread throughout your body. It is the second-leading cause of death in the world. Cancer gene therapy is a technique used for the treatment of cancer where therapeutic DNA is being introduced into the gene of the patient with cancer. With the advancement in technology, the gene therapy market has transformed over the recent few years. Cancer gene therapy is a technique used for the treatment of cancer where therapeutic DNA is being introduced into the gene of the patient with cancer. Owing to the high success rate during the preclinical and clinical trials, cancer gene therapy has gained popularity. Many techniques are used for cancer gene therapy, for example, a procedure where the mutated gene is being replaced with a healthy gene or inactivation of the gene whose function is abnormal. Recently, a new technique has been developed, where new genes are introduced into the body to help fight against cancer cells.

The rise in the prevalence of cancer, the benefits of cancer gene therapy over conventional cancer therapies, and the advancement in this field are the major factors that drive the market growth. In addition, the surge in government support, ethical acceptance of gene therapy for cancer treatment, and rise in biotechnological funding encourage the R&D activities for cancer gene therapy and thus fuel the growth of the cancer gene therapy market. In addition rise in awareness regarding cancer gene therapy are the major factors that drive the global cancer gene therapy market growth. In addition, an increase in government support for research in gene therapy, ethical acceptance of gene therapy for cancer treatment, and a rise in the prevalence of cancer boost the growth of the cancer gene therapy market. However, the high cost associated with the treatment and unwanted immune responses is expected to restrain the market growth.

The cancer gene therapy market is segmented on the basis of therapy, end-user, and region. By therapy, it is categorized into gene-induced immunotherapy, oncolytic virotherapy, and gene transfer. By end-user, it is categorized into hospitals, diagnostic centers, and research institutes. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players operating in the global cancer gene therapy market include Adaptimmune, GlaxoSmithKline, Bluebird bio, Inc., Merck, Celgene, Shanghai Sunway Biotech, BioCancell, Shenzhen SiBionoGeneTech, SynerGene Therapeutics, and OncoGenex Pharmaceuticals.

Other prominent players in the value chain include Genelux Corporation, Cell Genesys, Advantagene, GenVec, BioCancell, Celgene, Epeius Biotechnologies, Introgen Therapeutics, Ziopharm Oncology, Shenzhen SiBionoGeneTech, and Altor Bioscience.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cancer gene therapy market analysis from 2020 to 2030 to identify the prevailing cancer gene therapy market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the cancer gene therapy market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global cancer gene therapy market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Therapy

  • Gene Induced Immunotherapy
  • Oncolytic Virotherapy
  • Gene Transfer

By End User

  • Hospitals
  • Diagnostic centers
  • Research Institutes

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest Of Asia Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Bristol Myers Squibb Co.
    • Novartis
    • Amgen Inc.
    • Glaxosmithkline PLC
    • Kayropharma Therapeutics
    • Gilead Sciences
    • Adapta Immue
    • Genulex Corporation
    • SynerGene Therapeutics
    • shanghai sunway biotech

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: CANCER GENE THERAPY MARKET, BY THERAPY

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Gene Induced Immunotherapy
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Oncolytic Virotherapy
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Gene Transfer
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country

CHAPTER 5: CANCER GENE THERAPY MARKET, BY END USER

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Hospitals
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Diagnostic centers
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Research Institutes
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country

CHAPTER 6: CANCER GENE THERAPY MARKET, BY REGION

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 North America
    • 6.2.1 Key trends and opportunities
    • 6.2.2 North America Market size and forecast, by Therapy
    • 6.2.3 North America Market size and forecast, by End User
    • 6.2.4 North America Market size and forecast, by country
      • 6.2.4.1 U.S.
      • 6.2.4.1.1 Market size and forecast, by Therapy
      • 6.2.4.1.2 Market size and forecast, by End User
      • 6.2.4.2 Canada
      • 6.2.4.2.1 Market size and forecast, by Therapy
      • 6.2.4.2.2 Market size and forecast, by End User
      • 6.2.4.3 Mexico
      • 6.2.4.3.1 Market size and forecast, by Therapy
      • 6.2.4.3.2 Market size and forecast, by End User
  • 6.3 Europe
    • 6.3.1 Key trends and opportunities
    • 6.3.2 Europe Market size and forecast, by Therapy
    • 6.3.3 Europe Market size and forecast, by End User
    • 6.3.4 Europe Market size and forecast, by country
      • 6.3.4.1 Germany
      • 6.3.4.1.1 Market size and forecast, by Therapy
      • 6.3.4.1.2 Market size and forecast, by End User
      • 6.3.4.2 France
      • 6.3.4.2.1 Market size and forecast, by Therapy
      • 6.3.4.2.2 Market size and forecast, by End User
      • 6.3.4.3 U.K.
      • 6.3.4.3.1 Market size and forecast, by Therapy
      • 6.3.4.3.2 Market size and forecast, by End User
      • 6.3.4.4 Italy
      • 6.3.4.4.1 Market size and forecast, by Therapy
      • 6.3.4.4.2 Market size and forecast, by End User
      • 6.3.4.5 Spain
      • 6.3.4.5.1 Market size and forecast, by Therapy
      • 6.3.4.5.2 Market size and forecast, by End User
      • 6.3.4.6 Rest of Europe
      • 6.3.4.6.1 Market size and forecast, by Therapy
      • 6.3.4.6.2 Market size and forecast, by End User
  • 6.4 Asia-Pacific
    • 6.4.1 Key trends and opportunities
    • 6.4.2 Asia-Pacific Market size and forecast, by Therapy
    • 6.4.3 Asia-Pacific Market size and forecast, by End User
    • 6.4.4 Asia-Pacific Market size and forecast, by country
      • 6.4.4.1 Japan
      • 6.4.4.1.1 Market size and forecast, by Therapy
      • 6.4.4.1.2 Market size and forecast, by End User
      • 6.4.4.2 China
      • 6.4.4.2.1 Market size and forecast, by Therapy
      • 6.4.4.2.2 Market size and forecast, by End User
      • 6.4.4.3 Australia
      • 6.4.4.3.1 Market size and forecast, by Therapy
      • 6.4.4.3.2 Market size and forecast, by End User
      • 6.4.4.4 India
      • 6.4.4.4.1 Market size and forecast, by Therapy
      • 6.4.4.4.2 Market size and forecast, by End User
      • 6.4.4.5 South Korea
      • 6.4.4.5.1 Market size and forecast, by Therapy
      • 6.4.4.5.2 Market size and forecast, by End User
      • 6.4.4.6 Rest Of Asia Pacific
      • 6.4.4.6.1 Market size and forecast, by Therapy
      • 6.4.4.6.2 Market size and forecast, by End User
  • 6.5 LAMEA
    • 6.5.1 Key trends and opportunities
    • 6.5.2 LAMEA Market size and forecast, by Therapy
    • 6.5.3 LAMEA Market size and forecast, by End User
    • 6.5.4 LAMEA Market size and forecast, by country
      • 6.5.4.1 Brazil
      • 6.5.4.1.1 Market size and forecast, by Therapy
      • 6.5.4.1.2 Market size and forecast, by End User
      • 6.5.4.2 Saudi Arabia
      • 6.5.4.2.1 Market size and forecast, by Therapy
      • 6.5.4.2.2 Market size and forecast, by End User
      • 6.5.4.3 South Africa
      • 6.5.4.3.1 Market size and forecast, by Therapy
      • 6.5.4.3.2 Market size and forecast, by End User
      • 6.5.4.4 Rest of LAMEA
      • 6.5.4.4.1 Market size and forecast, by Therapy
      • 6.5.4.4.2 Market size and forecast, by End User

CHAPTER 7: COMPANY LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Key developments

CHAPTER 8: COMPANY PROFILES

  • 8.1 Bristol Myers Squibb Co.
    • 8.1.1 Company overview
    • 8.1.2 Company snapshot
    • 8.1.3 Operating business segments
    • 8.1.4 Product portfolio
    • 8.1.5 Business performance
    • 8.1.6 Key strategic moves and developments
  • 8.2 Novartis
    • 8.2.1 Company overview
    • 8.2.2 Company snapshot
    • 8.2.3 Operating business segments
    • 8.2.4 Product portfolio
    • 8.2.5 Business performance
    • 8.2.6 Key strategic moves and developments
  • 8.3 Amgen Inc.
    • 8.3.1 Company overview
    • 8.3.2 Company snapshot
    • 8.3.3 Operating business segments
    • 8.3.4 Product portfolio
    • 8.3.5 Business performance
    • 8.3.6 Key strategic moves and developments
  • 8.4 Glaxosmithkline PLC
    • 8.4.1 Company overview
    • 8.4.2 Company snapshot
    • 8.4.3 Operating business segments
    • 8.4.4 Product portfolio
    • 8.4.5 Business performance
    • 8.4.6 Key strategic moves and developments
  • 8.5 Kayropharma Therapeutics
    • 8.5.1 Company overview
    • 8.5.2 Company snapshot
    • 8.5.3 Operating business segments
    • 8.5.4 Product portfolio
    • 8.5.5 Business performance
    • 8.5.6 Key strategic moves and developments
  • 8.6 Gilead Sciences
    • 8.6.1 Company overview
    • 8.6.2 Company snapshot
    • 8.6.3 Operating business segments
    • 8.6.4 Product portfolio
    • 8.6.5 Business performance
    • 8.6.6 Key strategic moves and developments
  • 8.7 Adapta Immue
    • 8.7.1 Company overview
    • 8.7.2 Company snapshot
    • 8.7.3 Operating business segments
    • 8.7.4 Product portfolio
    • 8.7.5 Business performance
    • 8.7.6 Key strategic moves and developments
  • 8.8 Genulex Corporation
    • 8.8.1 Company overview
    • 8.8.2 Company snapshot
    • 8.8.3 Operating business segments
    • 8.8.4 Product portfolio
    • 8.8.5 Business performance
    • 8.8.6 Key strategic moves and developments
  • 8.9 SynerGene Therapeutics
    • 8.9.1 Company overview
    • 8.9.2 Company snapshot
    • 8.9.3 Operating business segments
    • 8.9.4 Product portfolio
    • 8.9.5 Business performance
    • 8.9.6 Key strategic moves and developments
  • 8.10 shanghai sunway biotech
    • 8.10.1 Company overview
    • 8.10.2 Company snapshot
    • 8.10.3 Operating business segments
    • 8.10.4 Product portfolio
    • 8.10.5 Business performance
    • 8.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER GENE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
  • TABLE 2. CANCER GENE THERAPY MARKET REVENUE, FOR GENE INDUCED IMMUNOTHERAPY, BY REGION , 2020-2030,($MILLION)
  • TABLE 3. CANCER GENE THERAPY MARKET GENE INDUCED IMMUNOTHERAPY BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 4. CANCER GENE THERAPY MARKET REVENUE, FOR ONCOLYTIC VIROTHERAPY, BY REGION , 2020-2030,($MILLION)
  • TABLE 5. CANCER GENE THERAPY MARKET ONCOLYTIC VIROTHERAPY BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 6. CANCER GENE THERAPY MARKET REVENUE, FOR GENE TRANSFER, BY REGION , 2020-2030,($MILLION)
  • TABLE 7. CANCER GENE THERAPY MARKET GENE TRANSFER BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 8. GLOBAL CANCER GENE THERAPY MARKET, BY END USER, 2020-2030,($MILLION)
  • TABLE 9. CANCER GENE THERAPY MARKET REVENUE, FOR HOSPITALS, BY REGION , 2020-2030,($MILLION)
  • TABLE 10. CANCER GENE THERAPY MARKET HOSPITALS BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 11. CANCER GENE THERAPY MARKET REVENUE, FOR DIAGNOSTIC CENTERS, BY REGION , 2020-2030,($MILLION)
  • TABLE 12. CANCER GENE THERAPY MARKET DIAGNOSTIC CENTERS BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 13. CANCER GENE THERAPY MARKET REVENUE, FOR RESEARCH INSTITUTES, BY REGION , 2020-2030,($MILLION)
  • TABLE 14. CANCER GENE THERAPY MARKET RESEARCH INSTITUTES BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 15. CANCER GENE THERAPY MARKET, BY REGION, 2020-2030,($MILLION)
  • TABLE 16. NORTH AMERICA CANCER GENE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
  • TABLE 17. NORTH AMERICA CANCER GENE THERAPY MARKET, BY END USER, 2020-2030,($MILLION)
  • TABLE 18. NORTH AMERICA CANCER GENE THERAPY MARKET, BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 19. U.S. CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 20. U.S. CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 21. CANADA CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 22. CANADA CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 23. MEXICO CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 24. MEXICO CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 25. EUROPE CANCER GENE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
  • TABLE 26. EUROPE CANCER GENE THERAPY MARKET, BY END USER, 2020-2030,($MILLION)
  • TABLE 27. EUROPE CANCER GENE THERAPY MARKET, BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 28. GERMANY CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 29. GERMANY CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 30. FRANCE CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 31. FRANCE CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 32. U.K. CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 33. U.K. CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 34. ITALY CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 35. ITALY CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 36. SPAIN CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 37. SPAIN CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 38. REST OF EUROPE CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 39. REST OF EUROPE CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 40. ASIA-PACIFIC CANCER GENE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
  • TABLE 41. ASIA-PACIFIC CANCER GENE THERAPY MARKET, BY END USER, 2020-2030,($MILLION)
  • TABLE 42. ASIA-PACIFIC CANCER GENE THERAPY MARKET, BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 43. JAPAN CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 44. JAPAN CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 45. CHINA CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 46. CHINA CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 47. AUSTRALIA CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 48. AUSTRALIA CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 49. INDIA CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 50. INDIA CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 51. SOUTH KOREA CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 52. SOUTH KOREA CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 53. REST OF ASIA PACIFIC CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 54. REST OF ASIA PACIFIC CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 55. LAMEA CANCER GENE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
  • TABLE 56. LAMEA CANCER GENE THERAPY MARKET, BY END USER, 2020-2030,($MILLION)
  • TABLE 57. LAMEA CANCER GENE THERAPY MARKET, BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 58. BRAZIL CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 59. BRAZIL CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 60. SAUDI ARABIA CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 61. SAUDI ARABIA CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 62. SOUTH AFRICA CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 63. SOUTH AFRICA CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 64. REST OF LAMEA CANCER GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 65. REST OF LAMEA CANCER GENE THERAPY MARKET BY END USER 2020-2030,($MILLION)
  • TABLE 66.BRISTOL MYERS SQUIBB CO.: COMPANY SNAPSHOT
  • TABLE 67.BRISTOL MYERS SQUIBB CO.: OPERATING SEGMENTS
  • TABLE 68.BRISTOL MYERS SQUIBB CO.: PRODUCT PORTFOLIO
  • TABLE 69.BRISTOL MYERS SQUIBB CO.: NET SALES,
  • TABLE 70.BRISTOL MYERS SQUIBB CO.: KEY STRATERGIES
  • TABLE 71.NOVARTIS: COMPANY SNAPSHOT
  • TABLE 72.NOVARTIS: OPERATING SEGMENTS
  • TABLE 73.NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 74.NOVARTIS: NET SALES,
  • TABLE 75.NOVARTIS: KEY STRATERGIES
  • TABLE 76.AMGEN INC.: COMPANY SNAPSHOT
  • TABLE 77.AMGEN INC.: OPERATING SEGMENTS
  • TABLE 78.AMGEN INC.: PRODUCT PORTFOLIO
  • TABLE 79.AMGEN INC.: NET SALES,
  • TABLE 80.AMGEN INC.: KEY STRATERGIES
  • TABLE 81.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 82.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 83.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 84.GLAXOSMITHKLINE PLC: NET SALES,
  • TABLE 85.GLAXOSMITHKLINE PLC: KEY STRATERGIES
  • TABLE 86.KAYROPHARMA THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 87.KAYROPHARMA THERAPEUTICS: OPERATING SEGMENTS
  • TABLE 88.KAYROPHARMA THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 89.KAYROPHARMA THERAPEUTICS: NET SALES,
  • TABLE 90.KAYROPHARMA THERAPEUTICS: KEY STRATERGIES
  • TABLE 91.GILEAD SCIENCES: COMPANY SNAPSHOT
  • TABLE 92.GILEAD SCIENCES: OPERATING SEGMENTS
  • TABLE 93.GILEAD SCIENCES: PRODUCT PORTFOLIO
  • TABLE 94.GILEAD SCIENCES: NET SALES,
  • TABLE 95.GILEAD SCIENCES: KEY STRATERGIES
  • TABLE 96.ADAPTA IMMUE: COMPANY SNAPSHOT
  • TABLE 97.ADAPTA IMMUE: OPERATING SEGMENTS
  • TABLE 98.ADAPTA IMMUE: PRODUCT PORTFOLIO
  • TABLE 99.ADAPTA IMMUE: NET SALES,
  • TABLE 100.ADAPTA IMMUE: KEY STRATERGIES
  • TABLE 101.GENULEX CORPORATION: COMPANY SNAPSHOT
  • TABLE 102.GENULEX CORPORATION: OPERATING SEGMENTS
  • TABLE 103.GENULEX CORPORATION: PRODUCT PORTFOLIO
  • TABLE 104.GENULEX CORPORATION: NET SALES,
  • TABLE 105.GENULEX CORPORATION: KEY STRATERGIES
  • TABLE 106.SYNERGENE THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 107.SYNERGENE THERAPEUTICS: OPERATING SEGMENTS
  • TABLE 108.SYNERGENE THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 109.SYNERGENE THERAPEUTICS: NET SALES,
  • TABLE 110.SYNERGENE THERAPEUTICS: KEY STRATERGIES
  • TABLE 111.SHANGHAI SUNWAY BIOTECH: COMPANY SNAPSHOT
  • TABLE 112.SHANGHAI SUNWAY BIOTECH: OPERATING SEGMENTS
  • TABLE 113.SHANGHAI SUNWAY BIOTECH: PRODUCT PORTFOLIO
  • TABLE 114.SHANGHAI SUNWAY BIOTECH: NET SALES,
  • TABLE 115.SHANGHAI SUNWAY BIOTECH: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.CANCER GENE THERAPY MARKET SEGMENTATION
  • FIGURE 2.CANCER GENE THERAPY MARKET,2020-2030
  • FIGURE 3.CANCER GENE THERAPY MARKET,2020-2030
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.CANCER GENE THERAPY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11.CANCER GENE THERAPY MARKET,BY THERAPY,2020(%)
  • FIGURE 12.COMPARATIVE SHARE ANALYSIS OF GENE INDUCED IMMUNOTHERAPY CANCER GENE THERAPY MARKET,2020-2030(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ONCOLYTIC VIROTHERAPY CANCER GENE THERAPY MARKET,2020-2030(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF GENE TRANSFER CANCER GENE THERAPY MARKET,2020-2030(%)
  • FIGURE 15.CANCER GENE THERAPY MARKET,BY END USER,2020(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF HOSPITALS CANCER GENE THERAPY MARKET,2020-2030(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF DIAGNOSTIC CENTERS CANCER GENE THERAPY MARKET,2020-2030(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF RESEARCH INSTITUTES CANCER GENE THERAPY MARKET,2020-2030(%)
  • FIGURE 19.CANCER GENE THERAPY MARKET BY REGION,2020
  • FIGURE 20.U.S. CANCER GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 21.CANADA CANCER GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 22.MEXICO CANCER GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 23.GERMANY CANCER GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 24.FRANCE CANCER GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 25.U.K. CANCER GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 26.ITALY CANCER GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 27.SPAIN CANCER GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 28.REST OF EUROPE CANCER GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 29.JAPAN CANCER GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 30.CHINA CANCER GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 31.AUSTRALIA CANCER GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 32.INDIA CANCER GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 33.SOUTH KOREA CANCER GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 34.REST OF ASIA PACIFIC CANCER GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 35.BRAZIL CANCER GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 36.SAUDI ARABIA CANCER GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 37.SOUTH AFRICA CANCER GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 38.REST OF LAMEA CANCER GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 39. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 40. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 41. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 42.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 43.COMPETITIVE DASHBOARD
  • FIGURE 44.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 45.BRISTOL MYERS SQUIBB CO..: NET SALES ,($MILLION)
  • FIGURE 46.NOVARTIS.: NET SALES ,($MILLION)
  • FIGURE 47.AMGEN INC..: NET SALES ,($MILLION)
  • FIGURE 48.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)
  • FIGURE 49.KAYROPHARMA THERAPEUTICS.: NET SALES ,($MILLION)
  • FIGURE 50.GILEAD SCIENCES.: NET SALES ,($MILLION)
  • FIGURE 51.ADAPTA IMMUE.: NET SALES ,($MILLION)
  • FIGURE 52.GENULEX CORPORATION.: NET SALES ,($MILLION)
  • FIGURE 53.SYNERGENE THERAPEUTICS.: NET SALES ,($MILLION)
  • FIGURE 54.SHANGHAI SUNWAY BIOTECH.: NET SALES ,($MILLION)